GlaxoSmithKline and Theravance, a biopharmaceutical company, have announced positive results from three, separate Phase IIb studies assessing efficacy and safety of GSK's inhaled corticosteroid fluticasone furoate across a range of eight doses in over 1,800 patients with mild, moderate and severe asthma.
For more details check the site
http://drugdiscovery.pharmaceutical-business-review.com/news/gsk_and_theravance_report_positive_results_from_phase_iib_asthma_studies_090209
No comments:
Post a Comment